EGeen's key business focus is to conduct drug development via expeditious and cost-effective clinical trials by taking advantage of several unique assets built since the founding of the company in 2001. In addition to the clinical database, EGeen's extensive capabilities for DNA and biomarker profile analyses allow the company, when appropriate, to complement the clinical trials with pharmacogenetics for more precise, individualized treatments.